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REVIEW CURRENTOPINION Outcome measurement of refractory
breathlessness: endpoints and important
differences Copyright 
www.supportiveandpalliativeca¨ a,b a cMagnus Ekstrom , David C. Currow , and Miriam J. JohnsonPurpose of review
Standardized measurement of self-rated breathlessness using appropriate tools is essential for research and
clinical care. The purpose was to review recent advances in the measurement of breathlessness and the
minimal clinically important differences (MCIDs) in intensity of chronic breathlessness.
Recent findings
Two tools have been validated in people with chronic obstructive pulmonary disease (COPD) to measure
daily symptoms and breathlessness related to daily activities. Two multidimensional tools have been
developed for different settings and aetiologies, which measure both the perceived intensity,
unpleasantness, quality of breathlessness, and the person’s emotional response to it. MCIDs have been
reported for the intensity of chronic refractory breathlessness, the daily symptom diary, and breathlessness
related to daily activities in COPD.
Summary
There have been substantial developments in instruments able to provide reliable and valid unidimensional
and multidimensional measurement of self-reported breathlessness and in the understanding of the MCID for
chronic breathlessness. Routine use of agreed outcome measures in clinical practice and research are
crucial steps to improve our understanding of the science of breathlessness and its impact on patients’
outcomes.
Keywords
breathlessness, dyspnea, minimal clinically important difference, outcome measureaDiscipline of Palliative and Supportive Services, Flinders University,
Adelaide, Australia, bDepartment of Clinical Sciences, Division of Respir-
atory Medicine & Allergology, Lund University, Lund, Sweden and cHull
York Medical School, University of Hull, UK
Correspondence to Magnus Ekström, Discipline of Palliative and
Supportive Services, Flinders University, Adelaide 5001, Australia.
Tel: +61 447485097; e-mail: pmekstrom@gmail.com
Curr Opin Cardiol 2015, 9:238–243
DOI:10.1097/SPC.0000000000000147
This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where
it is permissible to download and share the work provided it is properly
cited. The work cannot be changed in any way or used commercially.INTRODUCTION
Breathlessness is the subjective experience of breath-
ing discomfort that consists of qualitatively distinct
sensations that vary in intensity [1]. A useful model
identifies multiple dimensions of this symptom that
can be differentiated by the individual: the experi-
enced intensity and unpleasantness, the associated
emotional response, and the functional impact on
the person’s life [1]. Breathlessness, which persists
despite optimal medical management of underlying
disease(s), is termed to be refractory [2]. Refractory
breathlessness is common in advanced illness,
increasing in prevalence as death approaches across
a range of underlying diseases [3
&&
]. It is associated
with limited physical activity, deconditioning,
increased anxiety and depression, impaired quality
of life, loss of the will to live near death, increased
risk of hospitalization, and earlier death [1,4
&
].
The importance of breathlessness has been high-
lighted in recent years. For instance, breathlessness© 2015 Wolters Kluwer 
re.comhas been included in the evaluation of disease
severity [5
&
] and is a good measure for determining




Despite the high prevalence and its serious
impact, breathlessness remains frequently underre-
ported, unmeasured, and undertreated in clinicalHealth, Inc. All rights reserved.
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KEY POINTS
 Several tools for measuring breathlessness have been
developed to comply with regulatory requirements for
valid endpoints in randomized trials.
 Unidimensional tools include measures of severity
breathlessness in daily life and related to daily activities
in COPD.
 Multidimensional tools include the dyspnea-12 and
the MDP.
 The MCID has been determined for ratings of chronic
refractory breathlessness, severity in daily life, and
breathlessness related to daily activities.
Outcome measurement of refractory breathlessness Ekström et al.practice [6
&
]. Standardized measurement is essential
to identify the presence and quantify the severity of
breathlessness, to initiate evidence-based manage-
ment and demonstrate effectiveness of services [7].
The level of breathlessness should be reassessed
routinely in the clinic to evaluate the patient’s
response, risk for adverse events, and need for fol-
low-up and further treatment [7].
As breathlessness is a subjective sensation,
measurement should be by self-report unless this
is not possible, in which case proxy measures should
be sought [1,7]. There is currently no consensus of or
gold standard for which measurement tools to use
[1,8–10]. Tools can be categorized as unidimen-
sional, measuring one aspect of breathlessness, for
example, visual analogue scale (VAS) or numeric
rating scale (NRS) for intensity or unpleasantness,
the Borg scale for exertion induced intensity, or
the modified Medical Research Council Dyspnea
(mMRC) for impact on function [1]. Tools that
measure several aspects of breathlessness are called
multidimensional and include the Cancer Dysp-
noea Scale (CDS) and the Chronic Respiratory
Disease Questionnaire (CRQ) [9–11].
Parallel to the importance of measuring breath-
lessness in clinical practice, there has been a growing
interest in measures of breathlessness as endpoints
in randomized controlled trials (RCTs) [1,8–10,12
&
].




The minimal clinically important difference
(MCID) is a fundamental concept when evaluating
change or effect of treatment both in clinical trials
and practice [12
&
]. The MCID is defined as the small-
est difference in score in the domain of interest,
which patients perceive as beneficial and which
would mandate, in the absence of troublesome si-
de-effects and excessive cost, a change in the
patient’s management [14]. Recent years have seen Copyright © 2015 Wolters Kluwe
1751-4258 Copyright  2015 Wolters Kluwer Health, Inc. All rights resea rapid progress in the development of patient-
reported outcomes, and the publication of several
validated measurement tools of different aspects
of breathlessness.
The aim of this article was to critically review
recent advances regarding the measurement and
clinically important difference of chronic breath-
lessness in people with advanced, life-limiting
disease.Search strategy
We searched Medline up to January 29, 2015 using
the search terms (dyspnea/dyspnea/breathlessness/
shortness of breath/breathing difficult) OR (pallia-
tive care/palliative/palliation/terminal/advanced
disease/severe disease) AND (measure/outcome/
endpoint/clinically important difference/MID/
MCID). Searches were restricted to adults and
articles in English. Reference list of identified
articles and personal libraries were searched, includ-
ing for articles in press. The search covered the latest
research captured over the last 3 years, as few papers
were published in 2014. The selection criteria for
inclusion in the review were that the article pro-
vided quantitative data on the measurement of self-
reported breathlessness in severe or life-limiting
disease.MEASUREMENT OF BREATHLESSNESS
Tools published in recent years (Table 1) include the
unidimensional exacerbations of chronic pulmon-
ary disease respiratory symptom (E-RS) diary of daily
symptom severity (E-RS) [13
&&
] and a score of short-
ness of breath with daily activities (SOBDA) in COPD
[15
&
]. Multidimensional tools include the Dyspnea-
12 questionnaire [16] and the Multidimensional
Dyspnea Profile (MDP) [17–19
&&
]. The tools (Table
1) were all developed to comply with Food and Drug
Administration regulatory requirements for valid
endpoints in RCTs [13
&&
].
We also identified an article that examined the
level of agreement between proxy assessment of
breathlessness by healthcare professionals and
patient self-report [20
&
].Unidimensional tools of daily symptoms and
breathlessness related to daily activities:
exacerbations of chronic pulmonary disease
respiratory symptom and shortness of breath
with daily activities
E-RS is a diary of the severity of respiratory symp-
toms in stable COPD [13
&&
]. It consists of 11 items
from a tool, which was originally developed forr Health, Inc. All rights reserved.
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Table 1. Included tools and MCIDs for breathlessness
Tools Dimensions of breathlessness Validation populations Anchor-based MCID
Unidimensional
ER-S Intensity in daily life Stable COPD outpatients 1 point
VAS Intensity Refractory chronic breathlessness
(COPD, ILD, cancer, and heart failure)
9 mm (95% CI, 2.1 to 15.8)
SOBDA Intensity related to daily activities COPD outpatients 0.13–0.25 points
Multidimensional
Dyspnea-12 Breathing discomfort, sensory qualities,
and emotional responses, not related
to activity
Asthma, COPD, ILD, and heart failure No MCIDs reported
MDP Breathing discomfort, sensory qualities,
and emotional responses, not related
to activity
Patient seeking an emergency
department for acute breathlessness
No MCIDs reported
COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; MCID, minimal clinically important difference; MDP, Multidimensional Dyspnea Profile;
SOBDA, shortness of breath with daily activities; VAS, 100-mm visual analogue scale.
Respiratory problemsmeasuring symptoms during COPD exacerbations
[21]. Items involve the presence and severity of
symptoms ‘today,’ and relate to personal care,
indoor, and outdoor activities. Content validity
was explored through interviews with COPD
patients. The diary was then validated in 188
patients with stable COPD [52% females; mean
forced expiratory volume in 1 s (FEV1) 51% of pre-
dicted] over 7 days [13
&&
]. Factor analysis showed
that the diary measured three underlying con-
structs: breathlessness; cough and sputum; and
chest symptoms (congestion, tightness and discom-
fort). The breathlessness domain (range 0–17 points
with higher scores indicating more severe breath-
lessness) showed good reliability, test–retest repro-
ducibility, and external validity as supported by a
strong correlation with health-related quality of
life, mMRC breathlessness score, FEV1, and rescue
medication use.
Responsiveness over 3 months was shown using
data from three prospective clinical trials [22
&&
]. The
E-RS is a validated diary to measure the severity of
breathlessness as a summary score in daily life, for
people with COPD.
Wilcox et al. validated the first questionnaire
specifically for the measurement of SOBDA for use in
both clinical trials and care of people with COPD
[15
&
]. Questions were based on qualitative inter-
views and validated over 28 days in 334 COPD
patients (48% females; mostly moderate to severe
airflow limitation) recruited from medicine clinics
in the USA. Using Rasch analysis, 13 items were
found to measure breathlessness during daily activi-
ties and were included in the final SOBDA question-
naire [15
&
]. The mean weekly SOBDA score (range 1–
4 with greater scores indicating higher activity-
related breathlessness) was found to account for Copyright © 2015 Wolters Kluwer 
240 www.supportiveandpalliativecare.comdaily variations in activity, had high reliability
and validity, and was more informative than the
mean daily score.
Responsiveness was shown over 6 weeks using
data from a placebo-controlled RCT of inhaled glu-
cocorticoid and/or bronchodilator in 336 COPD
patients [23
&&
]. The weekly mean SOBDA score is a
reliable, valid, and responsive measure of breath-
lessness during daily activities in COPD [23
&&
].Multidimensional tools: Dyspnea-12 and
Multidimensional Dyspnea Profile
The Dyspnea-12 is a summary score of a person’s
severity of breathlessness, which requires no refer-
ence to activity [16]. The score was developed using
Rasch analysis and has been validated in patients
with asthma, COPD, interstitial lung disease, and
heart failure [16,24,25]. The Dyspnea-12 consists of
12 descriptor items rated on a 4-point Likert scale
(none, mild, moderate, and severe) by recall of the
severity of breathlessness ‘these days’ [16]. The over-
all score ranges between 0 and 36 with higher scores
indicating worse breathlessness. The Dyspnea-12
has shown good test properties with high internal
consistency, validity, and test-retest reliability over
2 weeks. The score captures several dimensions
including intensity, unpleasantness, and emotional
responses, as supported by strong correlations with
measures of anxiety and depression, health-related
quality of life, and mMRC breathlessness scale [16].
The Dyspnea-12 is short and relatively simple tool. It
does not clearly separate the dimensions of breath-
lessness, and the recall of breathlessness ‘these days’
might limit its usefulness in relation to some
settings, activities, or interventions. Dyspnea-12 is
available in several languages and has beenHealth, Inc. All rights reserved.
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Outcome measurement of refractory breathlessness Ekström et al.validated in a range of cardiopulmonary diseases
[16,24].
The MDP was developed to separately measure
the immediate breathing discomfort, sensory qual-
ities, and emotional responses irrespective of the
underlying cause of breathlessness in both labora-
tory and clinical, including acute care, settings
[17,18]. A revised version was recently published
by Banzett et al. [19
&&
] and can be used free of charge.
The MDP consists of 11 rating scale items between 0
(minimum) and 10 (maximum), which are divided
into two parts measuring separate constructs: the
immediate perception of breathlessness and the
emotional response. The first part includes a rating
of the immediate breathing discomfort as well as the
presence and intensity of five breathing qualities
(breathing effort, air hunger, chest tightness, mental
breathing effort, and breathing a lot). The second
part consists of ratings of the intensity of five
emotional responses: depression, anxiety, frustra-
tion, anger, and fright [19
&&
]. The time frame or
situation is defined by the user: ‘now,’ ‘over the past
24 hours,’ or ‘after this activity’ for example. The
tool has been validated in response to laboratory
stimuli [19
&&
], and in a clinical study of 151 patients
admitted to an emergency department (ED) for
acute breathlessness (29% had asthma, 27% COPD,
19% pneumonia, 13% heart failure, 13% other) [17].
Recall ratings were reliable and responsive over
hours during the ED visit supporting their useful-
ness. However, recall for items 4–6 weeks after the
ED visit was less reliable [18]. In contrast to the
multidimensional Dyspnea-12 and the CDS [11],
MDP captures the immediate breathing discomfort,
sensory qualities, and emotional responses separ-
ately during a user-defined period [19
&&
]. It was
developed based on previous research to enable
translation between laboratory and clinical settings,
across populations and diseases. MDP usually takes
around 3 minutes to complete [19
&&
]. To date, it is
available in English and French [19
&&
]. Validation in
further settings is warranted.Are professionals’ assessments of
breathlessness valid?
Although self-report by the patient is the gold stand-
ard for measures of breathlessness, this is sometimes
not possible and clinical management will rely on
proxy assessments. Proxy measures from informal
carers are known to be useful [26,27].
Simon et al. [20
&
] measured the consistency
between breathlessness assessment by healthcare
professionals (80% physicians and 18% nurses)
and self-report by 2623 inpatients in specialized
palliative care. Almost all (96%) of patients had Copyright © 2015 Wolters Kluwe
1751-4258 Copyright  2015 Wolters Kluwer Health, Inc. All rights resecancer (15% lung cancer). Breathlessness was rated
on a 4-point Likert scale (none, mild, moderate, and
severe).
The level of agreement was good for the presence
of any breathlessness but lower for rating severity. For
the presence of any breathlessness (mild or higher),
professionals’ reports had a positive predictive value
of 82% and a negative predictive value of 79% [20
&
].
The severity of breathlessness was correctly estimated
by professionals 66% of the time, with an even distri-
bution of overestimations and under estimations.
Agreement tended to be higher in people with better
functional status as compared with people with more
impaired function. Agreement did not differ between
physicians and nurses. The good proxy identification
of the presence of breathlessness might reflect the
strong emphasis on symptom management in
specialized palliative care. Proxy assessment of
breathlessness may be less accurate in other pro-
fessional disciplines [28].CLINICALLY IMPORTANT DIFFERENCES
Estimation
The MCID can be estimated using distribution-
based and anchor-based methods [12
&
].
The distribution-based method relies on the
assumption that the average MCID corresponds to
an effect size (change after intervention divided by
standard deviation of baseline score) [29]. However,
this method cannot determine whether this differ-
ence was perceived as clinically important by the
patient, and it is recommended that it is used in
conjunction with anchor-based methods [29].
Anchor-based methods estimate the MCID as the
average difference in breathlessness in patients expe-
riencing a small change in an anchor  another
relevant and validated assessment tool, such as qual-
ity of life, another measure of breathlessness, activity,
or a global impression of change [30
&
]. It is important
that the anchor is at least moderately associated with
the breathlessness score [12
&
]. More recently, patient
preference has been used as an anchor, which encom-




]. Of note, an MCID esti-
mate involves assumptions and uncertainties and
reflects a group average; the true MCID for the indi-
vidual might be higher of lower depending on a range
of clinical factors and circumstances [12
&
].Minimal clinically important difference of
chronic breathlessness intensity: visual
analogue scale
The MCID for chronic refractory breathlessness was
estimated by Johnson et al. [31
&&
] by pooling datar Health, Inc. All rights reserved.
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Respiratory problemsfrom three clinical trials of oral opioids vs. placebo
[2,33,34], and one observational phase II/IV study of
oral sustained-release morphine (n¼85; 49%
COPD, 28% cancer) for up to 3 months [35]. The
anchor-based MCID was the difference in mean
change of breathlessness between the preferred
and the nonpreferred study arm, according to
blinded self-reported treatment preference at the
end of each 4-day treatment period [31
&&
]. The
intensity of breathlessness was measured using a
100-mm VAS in one study [2] and a 0–10 NRS in
the other [33–35].
Distribution-based estimates were a mean
5.5-mm change for a small effect, 11.3 mm for
moderate, and 18.2 mm for a large improvement
[36]. The anchor-based MCID for improvement in
chronic refractory breathlessness was 9 mm [95%
confidence interval (CI), 2.1–15.8) on a 100-mm
VAS. The MCID for chronic breathlessness was
smaller than previous estimates for acute breathless-
ness in decompensated heart failure (22 mm) and
acute asthma (21 mm) [37,38]. This might reflect
that patients with chronic breathlessness, who often
have adapted to and lived with their symptoms for
many years, might appreciate even small changes in
breathlessness in an important way. The MCID
was consistent with a previous consensus [39] and
distribution-based estimate [40].
Using the same pooled data, Johnson et al. eval-
uated whether it is best to report MCID of absolute
or relative (percentage) change in chronic breath-
lessness. The estimated relative MCID was 14%
(change from baseline), but showed marked varia-
bility at lower baseline breathlessness values. The
absolute MCID was more stable across breathless-
ness intensities with the additional advantage that it
can be calculated by both methods, whereas a
relative MCID can be calculated by anchor-based
methods only.
Taken together, this analysis is the largest to
date and supports that studies of the intensity of
chronic breathlessness should be powered to detect
an absolute MCID of 9 mm on a 100-mm VAS
or, correspondingly, 1 point on a 0–10 NRS and
that this change equates to a moderate effect size
[31
&&
].Minimal clinically important difference of
severity of daily breathlessness:
exacerbations of chronic pulmonary disease
respiratory symptom
The MCID for the E-RS breathlessness diary was
estimated to 1.85 points using a distribution-based
method [13
&&
]. A second study suggested an anchor-
based MCID of 1 point (scale range: 0–17) both for Copyright © 2015 Wolters Kluwer 
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[22
&&
]. Change was defined as a change above the
MCID for the anchors St. George’s Respiratory
Questionnaire, a symptom questionnaire, and the
6-minute walk test [22
&&
].Minimal clinically important difference of
breathlessness related to daily activities:
shortness of breath with daily activities
The MCID for SOBDA was between 0.14 and 0.21
points using a distribution-based method [15
&
].
Anchor-based MCID was consistent at between




]. Anchors used to
define change were patient global assessment of
change and CRQ-SAS [23
&&
].Multidimensional tools: Dyspnea-12 and
Multidimensional Dyspnea Profile
We found no published data on the MCIDs for
overall or component scores of the Dyspnea-12 or
the MDP.CONCLUSION
There has been marked recent development in the
measurement of breathlessness. Validated tools are
now available for a symptom diary of daily life (E-RS)
and the severity of breathlessness during daily
activities in stable COPD (SOBDA), breathlessness
not related to activity as a multidimensional sum-
mary score (Dyspnea-12), or measuring dimensions
separately (MDP). MCIDs are available for the inten-
sity of chronic refractory breathlessness on a VAS or
NRS, E-RS, and SOBDA (Table 1). The MCID needs to
be established for the multidimensional Dyspnea-12
and MDP instruments.
Structured measurements by self-report are
imperative for identifying and treating breathless-
ness. The recent developments are likely to facilitate
reliable and valid measurement of the dimensions of
breathlessness across settings, populations, and eti-
ologies in both research and for the individual
patient in clinical care.Acknowledgements
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